COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020

COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020

Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine...

Full description

Bibliographic Details
Main Authors: François Bénézit, Audrey Le Bot, Stéphane Jouneau, Florian Lemaître, Charlotte Pronier, Pierre-Axel Lentz, Solène Patrat-Delon, Matthieu Revest, Vincent Thibault, Pierre Tattevin
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2020-10-01
Series:Emerging Infectious Diseases
Subjects:
COVID-19
2019 novel coronavirus disease
hydroxychloroquine
plasma concentration
sarcoidosis
France
Online Access:https://wwwnc.cdc.gov/eid/article/26/10/20-1816_article

Internet

https://wwwnc.cdc.gov/eid/article/26/10/20-1816_article

Similar Items